aspergillosis
ASPERGILLOSIS
Aspergillosis encompasses a variety of clinical syndromes depending on host immunity factors.
It is caused by Aspergillus, an ubiquitous, soil-dwelling, filamentous fungus that grows on soil, food, dead leaves, household dust, etc. It grows best at 37ºC and the small spores are easily inhaled and deposited deep in the lungs.
The most common pathogens are Aspergillus fumigatus, A. flavus, A. niger and A. terreus.
Aspergilloma is a conglomeration of intertwined Aspergillus hyphae, fibrin, mucus and cellular debris within a pulmonary cavity or an ectatic bronchus.

Aspergillosis Drug Information

Drug Information

Indication: Invasive aspergillosis; fluconazole-resistant serious invasive Candida infections (eg, C krusei); serious...

Indication: Invasive candidiasis in childn & adults. Oesophageal candidiasis in adults, adolescents ≥16 yr & el...

Indication: Invasive aspergillosis in patients w/ disease refractory to amphotericin B or intolerant to these drugs. Fusar...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Vulvovag candidosis, pityriasis versicolor, dermatomycosis, oral candidosis, onychomycosis caused by dermatoph...

Indication: Allergic, collagen, dermatological, GI, desquamative gingivitis, hematologic, tuberculous meningitis, ophth, r...

Indication: Bronchial asthma, allergic disease, RA, juvenile RA, rheumatoid myocarditis, rheumatic myelitis, psoriasis, os...

Indication: Primary or secondary adrenocortical insufficiency; rheumatic & hematologic disorders; bronchial asthma; co...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Sep 2020
Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).
Roshini Claire Anthony, 18 Jul 2020

The concurrent occurrence of diabesity and COVID-19 may lead to more severe disease due to the latter, according to a presentation at the Opening Session of ENDO Online.

Pearl Toh, 2 days ago
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.